Low-Level Laser Therapy

Combining minoxidil with low-level laser therapy did not produce a statistically significant improvement in hair count or hair diameter compared to minoxidil alone in patients with androgenic alopecia.

Combination LLLT and minoxidil produced significantly greater increases in hair density and hair shaft diameter, and higher patient satisfaction, compared to minoxidil monotherapy.

Microtrauma-based treatments like microneedling, lasers, and PRP increase hair density and thickness in androgenetic alopecia and promote regrowth in alopecia areata.

A consensus of experts identified seven recommended interventions for AGA, including oral and topical finasteride, dutasteride, and minoxidil, while identifying 17 interventions that are not recommended.

The review identifies topical melanin stimulants, antioxidants, dietary supplements, and LLLT as promising approaches for managing gray hair.

Scalp cooling is the current standard for preventing chemotherapy-induced alopecia; minoxidil, photobiomodulation, and PRP are used to promote hair regrowth, though supporting evidence varies.

Emerging therapies such as low-level laser therapy, microneedling, platelet-rich plasma, and stem cell therapy show promise for promoting hair regrowth, while conventional treatments like minoxidil and finasteride remain effective but have limitations.

Various over-the-counter, prescription, and procedural treatments successfully promote hair growth, suggesting that a multifaceted, individualized approach is most effective.

Laser and light therapy combined with topical minoxidil significantly reduces alopecia severity scores and improves treatment response compared to minoxidil alone, with lower recurrence at 1 year and similar adverse event rates.

Various treatments including 5-alpha reductase inhibitors, oral minoxidil, and PRP show efficacy, though evidence for some newer or non-pharmacological methods remains limited.

Standard treatments like topical minoxidil and oral finasteride are established, while newer modalities like PRP, LLLT, and oral minoxidil show encouraging results but lack standardized protocols.

Chemotherapy-induced alopecia affects approximately 65% of patients; current FDA-cleared prevention is limited to scalp cooling, while regrowth options include minoxidil, PBMT, and PRP.

The review discusses various promising topical, oral, and energy-based therapies, noting growing evidence for their efficacy in treating hair loss.

LLLT appears to be effective for treating pattern hair loss in both men and women, showing significant increases in hair diameter or density.

The review outlines various current and emerging therapies for hair loss, including pharmacological agents, devices, and cellular therapies.

The review discusses the pathophysiology and various emerging treatments such as microneedling, LLLT, and autologous fat transfer for female pattern hair loss.

The review outlines various FDA-approved and non-FDA-approved therapies for AGA, emphasizing that treatment selection must balance efficacy, side effects, compliance, and cost.

The review suggests that low-level laser therapy may promote hair growth in androgenetic alopecia, although the magnitude of benefit varies across studies.

Fractional laser and microneedling, especially when combined with topical agents, show promise for promoting hair regrowth in alopecia areata based on limited small studies.

Low-level laser therapy showed superior relative effects for hair regrowth compared to other non-surgical treatments, while PRP, finasteride, minoxidil, and dutasteride demonstrated approximately equivalent mean changes in hair count.

First-line therapies recommended include oral finasteride 1 mg daily, oral dutasteride 0.5 mg daily, topical 5% minoxidil twice daily for MPHL and topical 1% minoxidil twice daily for FPHL, along with low-level laser therapy and hair transplantation.

The review highlights several emerging therapies, including novel excipients for oral minoxidil, dutasteride, and finasteride; topical prostaglandin modulators; low-level laser therapy; Wnt pathway activators and stem cell treatments for androgenetic alopecia; JAK inhibitors for alopecia areata; antiandrogens and pioglitazone for frontal fibrosing alopecia; and robotic-assisted follicular unit extraction for hair transplantation.

Hair transplant surgery is effective for creating natural-appearing hair in men, though optimal harvesting techniques and adjunctive therapies remain subjects of debate.

Minoxidil, finasteride, and low-level laser therapy were significantly more effective than placebo for promoting hair growth in men with androgenetic alopecia, and minoxidil was effective in women.

Topical minoxidil shows moderate efficacy in increasing hair regrowth and hair count in women with FPHL, with no clear advantage of 5% over 2% concentration; oral finasteride 1 mg is not more effective than placebo; low-level laser therapy may increase hair count but clinical relevance is uncertain.

FDA-cleared LLLT devices are safe and effective for promoting hair regrowth in MPHL and FPHL patients who have not responded to or cannot tolerate standard therapies.

Current treatments (minoxidil, finasteride) offer limited and non-permanent benefits; hair transplantation is the only permanent option, while other off-label agents and laser therapies are commonly used despite modest or inconsistent efficacy.

LLLT appears safe and effective for promoting hair regrowth in both men and women by stimulating epidermal stem cells and shifting follicles into the anagen phase.

Minoxidil and finasteride remain the standard treatments, with hair transplantation as a surgical option; dutasteride, ketoconazole, and prostaglandin analogues (latanoprost, bimatoprost) are used or under investigation, and low-level laser therapy is gaining popularity, though robust clinical trial data proving hair growth efficacy are limited.